A3 Adenosine Receptor Antagonists (U.S. Patent Number 6,376,521)

This invention relates to a method of decreasing intraocular pressure by administrating an A3 subtype adenosine receptor antagonist, a calmodulin antagonist or an antiestrogen such as tamoxifen.